CORVUS PHARMACEUTICALS INC (CRVS) Stock Income Statement
NASDAQ:CRVS - Nasdaq - US2210151005 - Common Stock - Currency: USD
| TTM (2025-3-31) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Operating Expenses | 31.22M | 27.55M | 23.41M | 32.57M | 38.63M | |||
| Research and Development | 22.76M | 19.39M | 16.53M | 24.47M | 29.12M | |||
| Selling, General, and Administrative Expenses | 8.45M | 8.16M | 6.88M | 8.10M | 9.52M | |||
| Operating Income | -31.22M | -27.55M | -23.41M | -32.57M | -38.63M | |||
| Interest Income/Expense | -1.94M | -1.37M | -3.70M | -9.35M | -4.85M | |||
| Other Income/Expense | -8.25M | -33.38M | 78.00K | 590.00K | 240.00K | |||
| Non Recurring Items | N/A | N/A | N/A | 0.00 | 0.00 | |||
| Income Before Taxes | -41.40M | -62.29M | -27.03M | -41.31M | -43.24M | |||
| Net Income | -41.40M | -62.29M | -27.03M | -41.31M | -43.24M | |||
| EBITDA | -31.13M | -27.46M | -23.26M | -32.20M | -38.17M | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.65 | -1.02 | -0.56 | -0.89 | -1.03 | |||
| Non GAAP EPS | -0.61 | -0.94 | -0.57 | -0.89 | -1.06 | |||
| Statistics | ||||||||
All data in USD